In the USA, the first tablet of the new drug class of PCSK9 inhibitors has been approved, which is intended to help high-risk patients lower their cholesterol levels more effectively as a cost-effective supplement to statin therapy, without the need for injections. (translated)
Tablette statt Spritze: Neuer Cholesterinsenker für Risikopatienten
